CA3062744A1 - Neurotrophins for use in the treatment of hearing loss - Google Patents

Neurotrophins for use in the treatment of hearing loss Download PDF

Info

Publication number
CA3062744A1
CA3062744A1 CA3062744A CA3062744A CA3062744A1 CA 3062744 A1 CA3062744 A1 CA 3062744A1 CA 3062744 A CA3062744 A CA 3062744A CA 3062744 A CA3062744 A CA 3062744A CA 3062744 A1 CA3062744 A1 CA 3062744A1
Authority
CA
Canada
Prior art keywords
neurotrophin
ngf
use according
composition
previous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3062744A
Other languages
English (en)
French (fr)
Inventor
Maria DE PIZZOL
Andrea Aramini
Anna SIRICO
Mara Zippoli
Giuseppina Acerra
Simone Luca Mattiolo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe Farmaceutici SpA
Original Assignee
Acerra Giuseppina
De Pizzol Maria
Mattiolo Simone Luca
Sirico Anna
Zippoli Mara
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerra Giuseppina, De Pizzol Maria, Mattiolo Simone Luca, Sirico Anna, Zippoli Mara, Dompe Farmaceutici SpA filed Critical Acerra Giuseppina
Publication of CA3062744A1 publication Critical patent/CA3062744A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3062744A 2017-05-24 2018-05-22 Neurotrophins for use in the treatment of hearing loss Pending CA3062744A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17172659.9A EP3406259A1 (en) 2017-05-24 2017-05-24 Neurotrophins for use in the treatment of hearing loss
EP17172659.9 2017-05-24
PCT/EP2018/063310 WO2018215414A1 (en) 2017-05-24 2018-05-22 Neurotrophins for use in the treatment of hearing loss

Publications (1)

Publication Number Publication Date
CA3062744A1 true CA3062744A1 (en) 2018-11-29

Family

ID=58772736

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3062744A Pending CA3062744A1 (en) 2017-05-24 2018-05-22 Neurotrophins for use in the treatment of hearing loss

Country Status (11)

Country Link
US (1) US20200155647A1 (https=)
EP (2) EP3406259A1 (https=)
JP (1) JP2020520956A (https=)
KR (1) KR20200011951A (https=)
CN (1) CN110691607A (https=)
AU (1) AU2018274589A1 (https=)
BR (1) BR112019024504A2 (https=)
CA (1) CA3062744A1 (https=)
IL (1) IL270701A (https=)
RU (1) RU2019137430A (https=)
WO (1) WO2018215414A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4093387A4 (en) * 2020-01-24 2024-04-24 Dompé farmaceutici S.p.A. GROWTH FACTOR FORMULATION FOR A CONDITION ASSOCIATED WITH AN OTIC EVENT
WO2022221351A1 (en) * 2021-04-13 2022-10-20 Dompé Farmaceutici S.P.A. Treatment of neuropathic corneal pain with ngf
PL4452267T3 (pl) * 2021-12-23 2025-06-23 Cilcare Dev Pochodne 4-fenylo-tetrahydropirydyny do leczenia chorób słuchu
EP4316505A1 (en) * 2022-08-05 2024-02-07 Dompé farmaceutici S.p.a. Intranasal administration of ngf for the treatment of sensorineural hearing loss
KR102851394B1 (ko) * 2022-11-11 2025-09-04 단국대학교 천안캠퍼스 산학협력단 광반응성 하이드로젤을 이용한 분화유도인자 탑재 나노캡슐
EP4501346A1 (en) * 2023-08-04 2025-02-05 Dompe' Farmaceutici S.P.A. Method for the prevention of hearing loss induced by a platinum-based chemotherapy drug

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225282B1 (en) * 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
US7700111B2 (en) * 2002-01-17 2010-04-20 The Regents Of The University Of Michigan Auditory nerve protection and re-growth
WO2009062149A1 (en) * 2007-11-08 2009-05-14 Creighton University Methods for maintaining inner ear neurons
CN104203264B (zh) 2011-12-19 2018-08-28 瓦克化学有限公司 新型proNGF突变体及其在生产β-NGF中的用途
EP3328440A4 (en) * 2015-07-28 2019-01-16 Otonomy, Inc. TREATMENT WITH REDUCED TRK-B AND TRK-C ANTAGONISTS
CA2993645A1 (en) * 2015-07-28 2017-02-02 Otonomy, Inc. Trkb or trkc agonist compositions and methods for the treatment of otic conditions

Also Published As

Publication number Publication date
WO2018215414A1 (en) 2018-11-29
AU2018274589A1 (en) 2019-11-28
KR20200011951A (ko) 2020-02-04
RU2019137430A (ru) 2021-06-24
EP3630159A1 (en) 2020-04-08
IL270701A (en) 2020-01-30
CN110691607A (zh) 2020-01-14
EP3406259A1 (en) 2018-11-28
JP2020520956A (ja) 2020-07-16
RU2019137430A3 (https=) 2021-08-30
BR112019024504A2 (pt) 2020-06-23
US20200155647A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
US20200155647A1 (en) Neurotrophins for use in the treatment of hearing loss
Herran et al. In vivo administration of VEGF-and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson’s disease
JP7033789B2 (ja) トリグリセリド耳用製剤とその使用
Chen et al. Injectable bio-responsive hydrogel for therapy of inflammation related eyelid diseases
KR101449785B1 (ko) 귀 질환 및 병태를 치료하기 위한 귀 조제물
García-Caballero et al. Photoreceptor preservation induced by intravitreal controlled delivery of GDNF and GDNF/melatonin in rhodopsin knockout mice
Yu et al. Complete restoration of hearing loss and cochlear synaptopathy via minimally invasive, single-dose, and controllable middle ear delivery of brain-derived neurotrophic Factor–Poly (dl-lactic acid-co-glycolic acid)-loaded hydrogel
AU2009271129A1 (en) Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
WO2010062413A1 (en) Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
KR20180037994A (ko) TrkB 또는 TrkC 아고니스트 조성물 및 귀 병태의 치료 방법
CA3087574A1 (en) Growth factor otic formulations
US20220409671A1 (en) Composition for preventing or treating ocular diseases comprising amniotic epithelial cell derived exosomes
US20080262415A1 (en) Enhanced wound healing
Puntel et al. Prolonged prevention of retinal degeneration with retinylamine loaded nanoparticles
JP2020520956A5 (https=)
WO2018140792A2 (en) Neurotrophin mutants for treating hearing loss and other otic disorders
Rousset et al. Poly-lactic acid-based biopolymer formulations are safe for sustained intratympanic dexamethasone delivery
JP2002087983A (ja) 筋萎縮性側索硬化症治療剤
AU2020230269B2 (en) Auris formulations for treating otic diseases and conditions
EP4173630A1 (en) Pharmaceutical composition comprising stem cell-conditioned medium and exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease
US20180221451A1 (en) Long acting liraglutide compositions
KR102653853B1 (ko) 약물　전달용 나노서스펜션 및 이의 용도
Hu Survival and Axonal Regeneration of Retinal Ganglion Cells in a Mouse Optic Nerve Crush Model After a Delayed Cell-Based Intravitreal Co-Therapy with Ciliary Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor
CN120154631A (zh) 一种负载褪黑素和甲钴胺的水凝胶缓释材料及其制备方法和应用
EP3922282A1 (en) New drug delivery system for ophtalmic use